OOIR: Observatory of International Research

Papers

(The TQCC of Immunotherapy is 6. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Pasotuxizumab, a BiTE^® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings	75
Currently available intravenous immunoglobulin contains antibodies reacting against severe acute respiratory syndrome coronavirus 2 antigens	66
Atezolizumab in advanced hepatocellular carcinoma: good things come to those who wait	65
A global picture: therapeutic perspectives for COVID-19	55
Notable response to nivolumab during the treatment of SMARCA4-deficient thoracic sarcoma: a case report	36
Real-world study of hepatic artery infusion chemotherapy combined with anti-PD-1 immunotherapy and tyrosine kinase inhibitors for advanced hepatocellular carcinoma	36
Immune checkpoint inhibitors and chemotherapy in first-line NSCLC: a meta-analysis	35
Interferons: role in cancer therapy	29
Immortal time bias in the association between toxicity and response for immune checkpoint inhibitors: a meta-analysis	29
Cytokine storm modulation in COVID-19: a proposed role for vitamin D and DPP-4 inhibitor combination therapy (VIDPP-4i)	29
Cross-neutralization activity against SARS-CoV-2 is present in currently available intravenous immunoglobulins	28
Atezolizumab with bevacizumab, paclitaxel and carboplatin was effective for patients with SMARCA4-deficient thoracic sarcoma	28
Tumor cell-based vaccine: an effective strategy for eradication of cancer cells	27
Systemic immune–inflammation index predicts prognosis of cancer immunotherapy: systemic review and meta-analysis	27
Fostamatinib: a review of its clinical efficacy and safety in the management of chronic adult immune thrombocytopenia	25
The tumor microenvironment of colorectal cancer metastases: opportunities in cancer immunotherapy	25
TYK2 as a therapeutic target in the treatment of autoimmune and inflammatory diseases	25
Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma	25
Antimicrobial/anticancer peptides: bioactive molecules and therapeutic agents	24
Immunotherapy for gastric cancer: a 2021 update	24
Therapeutics to tackle Omicron outbreak	22
Sublingual immunotherapy for food allergy and its future directions	22
Efficacy of immune checkpoint inhibitors and age in cancer patients	22
Serum neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in prognosticating immunotherapy efficacy	21
Concurrent Vogt–Koyanagi–Harada disease and impressive response to immune checkpoint blockade in metastatic melanoma	21

Sutimlimab for treatment of cold agglutinin disease: why, how and for whom?	21
Targeted allergen-specific immunotherapy within the skin improves allergen delivery to induce desensitization to peanut	20
Atherosclerosis: immunopathogenesis and strategies for immunotherapy	20
Efficacy of immune checkpoint inhibitor therapy in patients with RET fusion-positive non-small-cell lung cancer	19
Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function	19
COVID-19: the use of immunotherapy in metastatic lung cancer	18
Hematopoietic stem cell transplantation and chimeric antigen receptor T cell for relapsed or refractory diffuse large B-cell lymphoma	18
Blocking EGFR with nimotuzumab: a novel strategy for COVID-19 treatment	18
The rationale for targeting the JAK/STAT pathway in scleroderma-associated interstitial lung disease	17
Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy	16
Phase I studies of peptide vaccine cocktails derived from GPC3, WDRPUH and NEIL3 for advanced hepatocellular carcinoma	16
Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019	16
Cost–effectiveness analysis of nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced NSCLC	16
Obesity, COVID-19 and immunotherapy: the complex relationship!	16
Chimeric antigen receptor macrophage for glioblastoma immunotherapy: the way forward	15
Early change in peripheral CD4⁺ T cells associated with clinical outcomes of immunotherapy in gastrointestinal cancer	15
Non-coding RNA and immune-checkpoint inhibitors: friends or foes?	15
Development of hepatitis triggered by SARS-CoV-2 vaccination in patient with cancer during immunotherapy: a case report	15
Potential clinical and serological predictors of chronic spontaneous urticaria relapse in patients under omalizumab treatment	15
Immunity to glycan α-Gal and possibilities for the control of COVID-19	15
PD-L1 expression as a predictive biomarker for immune checkpoint inhibitors: between a dream and a nightmare	15
Tumor-infiltrating lymphocytes as a feasible adjuvant immunotherapy for osteosarcoma with a poor response to neoadjuvant chemotherapy	15
Romosozumab in the treatment of osteoporosis	14
Overcoming stromal barriers to immuno-oncological responses via fibroblast activation protein-targeted therapy	14
Immune checkpoint inhibitors for brain metastases in non-small-cell lung cancer: from rationale to clinical application	14
Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges	13
Immune checkpoint inhibitors use and effects on prognosis of COVID-19 infection: a systematic review and meta-analysis	13
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis	13
Psoriatic arthritis induced by anti-PD1 and treated with apremilast: a case report and review of the literature	13
Immune checkpoint inhibitors: review of the existing evidence and challenges in breast cancer	13
A metastatic intrahepatic cholangiocarcinoma treated with programmed cell death 1 inhibitor: a case report and literature review	13
Efficacy of immunotherapy inKRAS-mutant non-small-cell lung cancer with comutations	13
Cellular immunotherapy in gastric cancer: adoptive cell therapy and dendritic cell-based vaccination	13
Capillary-leak syndrome: an unrecognized early immune adverse effect of checkpoint-inhibitors treatment	13
MUC1 antibody-based therapeutics: the promise of cancer immunotherapy	12
Anti-PD-1 treatment-induced immediate central diabetes insipidus: a case report	12
Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy	12
Nivolumab plus ipilimumab for soft tissue sarcoma: a single institution retrospective review	12
Potential protective and therapeutic role of immune checkpoint inhibitors against viral infections and COVID-19	12
Outcomes following immunotherapy re-challenge after immune-related adverse event: systematic review and meta-analysis	12
Neutrophil and lymphocyte blood count as potential predictive indicators of nivolumab efficacy in metastatic non-small-cell lung cancer	11
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma	11
Pseudoprogression of extramedullary disease in relapsed acute lymphoblastic leukemia after CAR T-cell therapy	11
Safety of semi-depot house dust mite allergen extract in children and adolescents with allergic rhinitis and asthma	11
Immunotherapy in hematological malignancies: recent advances and open questions	11
A Phase I clinical trial of chimeric antigen receptor-modified T cells in patients with relapsed and refractory lymphoma	10
Pegcetacoplan treatment for geographic atrophy due to age-related macular degeneration: a plain language summary of the FILLY study	10
Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)	10
The safety and efficacy of immune-checkpoint inhibitors in patients with cancer and pre-existing autoimmune diseases	10
Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis	10

Experimental treatment of colorectal cancer in mice with human T cells electroporated with NKG2D RNA CAR	10
A review of secukinumab in psoriasis treatment	10
Immunotherapy in psoriasis	10
Immunotherapy for cholangiocarcinoma: a 2021 update	10
An anti-CD6 antibody for the treatment of COVID-19 patients with cytokine-release syndrome: report of three cases	9
Dupilumab use in atopic dermatitis and beyond in skin diseases	9
Front-line daratumumab-VTd versus standard-of-care in ASCT-eligible multiple myeloma: matching-adjusted indirect comparison	9
The immunotherapy revolution in genitourinary malignancies	9
Neurological adverse events following CAR T-cell therapy: a real-world analysis	9
Surrogate end points for survival in patients with advanced hepatocellular carcinoma treated with immune checkpoint inhibitors	9
COVID-19 in a patient with advanced Merkel cell carcinoma receiving immunotherapy	9
Use of immune checkpoint inhibitors in cancer patients with pre-existing sarcoidosis	9
Recovery of COVID-19 acute respiratory distress syndrome with tocilizumab: successful outcome in two critically ill patients	9
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases	9
Asthma immunotherapy and treatment approaches with mesenchymal stem cells	8
Obesity and immunotherapy: the surprisingly positive association!	8
Immune checkpoint inhibitors in luminal gastrointestinal malignancies: going beyond MSI-H/dMMR, TMB and PD-L1	8
Engineering chimeric antigen receptor-natural killer cells for cancer immunotherapy	8
Immunology of osteoporosis: relevance of inflammatory targets for the development of novel interventions	8
Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma	8
PD-1,CTLA4,PD-L1andPD-L2DNA methylation in papillary thyroid carcinoma	8
Immune cells and signatures characterize tumor microenvironment and predict outcome in ovarian and endometrial cancers	8
Efficacy of a 3-year course of sublingual immunotherapy for mite-induced allergic rhinitis with a 3-year follow-up	7
Prognosticating role of serum eosinophils on immunotherapy efficacy in patients with advanced melanoma	7
Secondary pneumothorax during immunotherapy in two patients with metastatic solid tumors; a new entity	7
Cost–effectiveness analysis of atezolizumab plus nab-paclitaxel for untreated metastatic triple-negative breast cancer	7
Treatment of EAE mice with Treg, G-MDSC and IL-2: a new insight into cell therapy for multiple sclerosis	7
Determinants of treatment for first-line immune-based combinations in metastatic renal cell carcinoma: a critical overview of recent evidence	7
Mechanism of acquired resistance to nivolumab in lung squamous cell carcinoma: case report and review of the literature	7
Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review	7
The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice	7
Overview of subcutaneous immunoglobulin 16.5% in primary and secondary immunodeficiency diseases	7
Hurdles for the wide implementation of photoimmunotherapy	7
Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer	7
Chemotherapy or chemo-immunotherapy as first-line treatment for extensive-stage small-cell lung cancer: a meta-analysis	7
Immunoregulatory T cell epitope peptides for the treatment of allergic disease	7
Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians	7
Immunotherapy versus standard chemotherapy for treatment of extensive-stage small-cell lung cancer: a systematic review	7
HLA loss of heterozygosity-mediated discordant responses to immune checkpoint blockade in squamous cell lung cancer with renal metastasis	7
Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review	7
Immune-checkpoint inhibitors in renal transplanted patients affected by melanoma: a systematic review	7
The mRNA COVID-19 vaccine in patients with cancer receiving checkpoint inhibitor therapy: what we know and what we don't	7
Eculizumab in the treatment of neuromyelitis optica spectrum disorder	7
Combined application of bevacizumab and PD-1 blockade displays durable treatment effects by increasing the infiltration and cytotoxic function of CD8⁺T cells in lung cancer	7
Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy	7
Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma	7
Acute interstitial nephritis and PR3-ANCA following reintroduction of pembrolizumab: a case report	7
Pembrolizumab-associated erythema nodosum in the treatment of metastatic melanoma	7
Real-world maintenance therapy and survival outcomes for pembrolizumab plus pemetrexed and platinum for non-small-cell lung cancer in USA	6
Managing viral hepatitis in cancer patients under immune checkpoint inhibitors: should we take the risk?	6
Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary	6
Lichenoid drug eruption on the lower lip caused by anti-PD-1 monoclonal antibody: a case report and literature review	6
Peripheral blood eosinophil count is associated with response to chemoimmunotherapy in metastatic triple-negative breast cancer	6
Therapeutic cancer vaccine therapy for acute myeloid leukemia	6
A new perspective on the potential application of RIPK1 in the treatment of sepsis	6
Subcutaneous immunoglobulin use in immunoglobulin-naive patients with primary immunodeficiency: a systematic review	6
Disseminated intravascular coagulation in advanced lung adenocarcinoma during first-line pembrolizumab	6
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy	6
Peptide vaccine with glucopyranosyl lipid A–stable oil-in-water emulsion for patients with resected melanoma	6
Small-cell breast carcinoma with response to atezolizumab: a case report	6
Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis	6
Severe chronic nonlichenoid oral mucositis in pembrolizumab-treated patients: new cases and a review of the literature	6
Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report	6
Long-term control of leptomeningeal disease after radiation therapy and nivolumab in a metastatic melanoma patient	6
Lights and shadows on the role of rhG-CSF in cancer patients during the COVID-19 pandemic and future perspectives of research	6
Effectiveness of durvalumab consolidation in stage III non-small-cell lung cancer: focus on treatment selection and prognostic factors	6
GO-BEYOND: a real-world study of persistence of golimumab in patients with axial spondyloarthritis and rheumatoid arthritis in Turkey	6
IL-13 antagonists in the treatment of atopic dermatitis	6
First-line treatment of advanced/metastatic melanoma with anti-PD-1 antibodies: multicenter experience in Poland	6
Delayed immune-related neutropenia with hepatitis by pembrolizumab	6
Designing novel immunocombinations in metastatic renal cell carcinoma	6